title: Development and evaluation of paclitaxel loaded PLGA:poloxamer blend nanoparticles for cancer chemotherapy.
abstract: This investigation described the development of novel PLGA:poloxamer blend nanoparticles for intravenous administration of paclitaxel in order to limit the cremophor-associated adverse effects. The developed formulation was well-characterized using various techniques including scanning electron microscopy, transmission electron microscopy, Fourier transform infrared spectroscopy and differential scanning calorimetry. The nanoparticles had an average particle size around 180nm and zeta potential of -22.7mV. The in vitro release study of nanoparticles exhibited biphasic release pattern. The non-hemolytic potential of the nanoparticles indicated the suitability of the developed formulation for intravenous administration. The PLGA:poloxamer blend nanoparticles showed significantly improved cytotoxicity in cell lines (MCF-7 and Colo-205), as compared to free drug. Further, the developed formulation was stable under the accelerated storage conditions. In conclusion, the results indicated that the developed polymeric formulation is a novel and potential alternative for the paclitaxel delivery.
authors.affiliation: Formulation & Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India. Electronic address: pngupta@iiim.ac.in.
authors.forename: Prem N
authors.initials: PN
authors.lastname: Gupta
authors.affiliation: Formulation & Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: Sharad
authors.initials: S
authors.lastname: Jain
authors.affiliation: Formulation & Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: Chetan
authors.initials: C
authors.lastname: Nehate
authors.affiliation: Formulation & Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: Noor
authors.initials: N
authors.lastname: Alam
authors.affiliation: Formulation & Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: Vaibhav
authors.initials: V
authors.lastname: Khare
authors.affiliation: Formulation & Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: Ravindra Dhar
authors.initials: RD
authors.lastname: Dubey
authors.affiliation: Formulation & Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: Ankit
authors.initials: A
authors.lastname: Saneja
authors.affiliation: Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: Smit
authors.initials: S
authors.lastname: Kour
authors.affiliation: Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
authors.forename: Shashank K
authors.initials: SK
authors.lastname: Singh
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000737:chemistry*; D055808:Drug Discovery; D004355:Drug Stability; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D061986:MCF-7 Cells; D053758:Nanoparticles / Q000737:chemistry*; D017239:Paclitaxel / Q000737:chemistry* / Q000494:pharmacology*; D010316:Particle Size; D020442:Poloxamer / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D013696:Temperature
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D020442:Poloxamer; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017239:Paclitaxel
keywords: Cytotoxicity; Drug delivery; Nanoparticles; Paclitaxel; Poloxamer